Compare ERIC & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ERIC | ZTS |
|---|---|---|
| Founded | 1876 | 1952 |
| Country | Sweden | United States |
| Employees | N/A | 14500 |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.7B | 29.0B |
| IPO Year | 2002 | 2012 |
| Metric | ERIC | ZTS |
|---|---|---|
| Price | $9.54 | $70.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $11.00 | ★ $154.18 |
| AVG Volume (30 Days) | ★ 7.1M | 3.2M |
| Earning Date | 04-17-2026 | 05-07-2026 |
| Dividend Yield | 1.82% | ★ 1.86% |
| EPS Growth | N/A | ★ 10.05 |
| EPS | N/A | ★ 3.08 |
| Revenue | N/A | ★ $9,467,000,000.00 |
| Revenue This Year | N/A | $5.63 |
| Revenue Next Year | $1.83 | $4.77 |
| P/E Ratio | ★ $12.13 | $22.83 |
| Revenue Growth | N/A | ★ 2.28 |
| 52 Week Low | $8.12 | $69.93 |
| 52 Week High | $13.77 | $148.79 |
| Indicator | ERIC | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 36.26 | 38.66 |
| Support Level | $9.25 | N/A |
| Resistance Level | $10.38 | $78.20 |
| Average True Range (ATR) | 0.17 | 1.58 |
| MACD | -0.06 | -0.29 |
| Stochastic Oscillator | 7.58 | 23.48 |
Ericsson is a networking equipment and software provider, primarily selling mobile networking equipment and services to wireless service providers. Ericsson operates in three segments: networks, cloud software and services, and enterprise. While large wireless carriers are its largest customers, Ericsson has expanded its offerings for large enterprises. These products and services include private 5G networking, contact centers as a service, and application performance interfaces. Ericsson aims to combine its 5G network expertise with cloud-native, as-a-service platforms offering a more comprehensive hardware and software package. Ericsson also monetizes its research and development investments by licensing patents to handset manufacturers.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.